Retractable Technologies Inc. Common Stock (RVP)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking at Retractable Technologies, a small medical-device maker with an $18.3 million market cap at the 2026-10-13 close of $0.61. The filed numbers show why it is classified as a TURNAROUND: fiscal 2025 revenue was $38.3 million and net loss was $12.6 million, or -$0.43 per diluted share. That followed a fiscal 2024 net loss of $11.9 million on $33.0 million of revenue and a fiscal 2023 net loss of $7.0 million on $43.6 million. The latest quarter, fiscal Q2 2026 ended 2026-06-30, offered a flip: revenue of $7.2 million and net income of $2.8 million, or $0.09 per diluted share, a 39.31% margin. But fiscal Q1 2026 lost $4.2 million, so this is volatile. FairStock's price-based metrics show P/B of 0.25, negative P/E of -5.08, ROE of -4.51%, ROCE of -9.40%, and FCF yield of -28.0% on -$5.1 million trailing free cash flow. Debt is minimal with D/E of 0.01, and EV/EBITDA is 3.63, but Altman Z of 0.69 signals distress. Piotroski is 5/9. The moat is not evident in these figures; revenue declined from $43.6 million in fiscal 2023 to $38.3 million in fiscal 2025, and cash is burning. The asset discount could be a margin of safety only if the recent profit is real and repeatable. I would demand several quarters of positive earnings and positive cash flow before trusting book value.

In plain English: Retractable Technologies makes safety syringes and other safety medical products for healthcare workers. The business has mostly been losing money, sales have been uneven, and cash flow is negative, though it did report a profitable quarter recently. At 61 cents a share, the price looks very low compared with its book value, but that cheapness reflects real doubts about whether the losses will stop.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer